Gilead Sciences CEO aims at widely available Coronavirus Treatment
Gilead Sciences CEO Daniel O’Day said on Friday that the company is focused on experimental coronavirus drug that is affordable and widely accessible. Gilead Sciences manufactures remdesivir and the company is working on an experimental treatment. CEO O’Day said that their aim is to reach more people once the drug shows positive results and receives drug agency approval.
Initial trials conducted with remdesivir shows that the drug helped patients recover more quickly from the illness compared to placebo treatment. Gilead said that the company research team is working on improving the treatment options. Due to coronavirus pandemic, many drug development teams are working on treatment and vaccine.
Gilead Sciences shot to fame as it developed hepatitis C treatment which is effective and easier to administer compared to other treatment options. The company manufactures and markets Solvadi and Harvoni as hepatitis treatments.
Talking about the company plans for treatment, O’Day said, “I can assure you that we’re all focused on making sure that we make this accessible and affordable to patients around the globe.” Gilead reported second-quarter earnings on Thursday, said it would work with international partners to expand production of the potential COVID-19 treatment.